NeuroSense Therapeutics Ltd.
NRSN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001875091
No open-market purchases or sales by NeuroSense Therapeutics Ltd. insiders were filed in the last 90 days; 12 institutions reported holding it in 13F filings for Q2 2026, worth $285.7K in total; no superinvestor holds it.
Other share classesNRSNW
Q2 2023 vs. Q1 2023
How the institutions holding NeuroSense Therapeutics Ltd. changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Q2 2023 | Change |
|---|---|---|---|
| Holders | 5 | 6 | +1 |
| Shares | 123.8K | 1.57M | +1.45M (+1,167.6%) |
| Value | $243.4K | $2.34M | +$2.09M (+860.7%) |
New holders (3)
Institutions that held NeuroSense Therapeutics Ltd. at the end of Q2 2023 but not at the end of Q1 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Armistice Capital, LLC | 1,266,000 | $1.89M | 0.05% |
| Point72 Asset Management, L.P. | 100,000 | $149.0K | 0.00% |
| JPMorgan Chase & Co | 1,304 | $1.90K | 0.00% |
Sold out (2)
Institutions that held NeuroSense Therapeutics Ltd. at the end of Q1 2023 and filed for Q2 2023 without it.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| Ground Swell Capital, LLC | 11,858 | $20.6K |
| UBS Group AG | 4,762 | $8.19K |